10-Q: Telomir Pharmaceuticals Boosts Cash, Eyes Global Rights for Telomir-1

Telomir Pharmaceuticals reported reduced net losses and increased cash reserves, driven by recent equity financings, while announcing a binding LOI to acquire worldwide rights for its lead candidate, Telomir-1.

Summary

• Telomir Pharmaceuticals, a pre-clinical stage biotechnology company, reported a net loss of $1.1 million for the three months ended September 30, 2025, a significant reduction from $6.0 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $8.4 million, an improvement from $13.6 million in the prior year period.
• Cash and cash equivalents increased substantially to $7.3 million as of September 30, 2025, up from $1.3 million at December 31, 2024.
• The company raised $3 million in equity financing from The Bayshore Trust, an affiliate of its largest shareholder, by issuing 1,000,000 restricted shares at $3.00 per share.
• An At The Market (ATM) offering generated $5,550,008 in net proceeds from the sale of 2,668,300 common shares during the nine months ended September 30, 2025, with an additional $1,003,200 net proceeds from 550,000 shares sold in October 2025.
• Telomir executed a binding Letter of Intent (LOI) on October 17, 2025, to acquire TELI Pharmaceuticals, Inc., a related party, to secure worldwide rights to its lead investigational therapy, Telomir-1.
• The LOI includes potential contributions of up to $5 million from certain TELI shareholders, with $1 million due at closing, $2 million upon IND acceptance, and $2 million upon Phase 1/2 initiation.
• Numerous positive preclinical results for Telomir-1 were reported between July and October 2025, demonstrating activity in cancer, aging, and degenerative disease models, including reversing epigenetic silencing, restoring mitochondrial function, inhibiting histone demethylase enzymes, and reducing tumor growth.
• Despite financial improvements, the company continues to incur losses and has a going concern warning, with current cash expected to fund operations only through the third quarter of 2026.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the explicit 'going concern' warning and continued operational losses, which are significant red flags for investors. While there are positives like reduced net losses, increased cash from recent financings, and promising preclinical data, these are overshadowed by the fundamental uncertainty of long-term viability without substantial future funding and successful clinical translation. The related-party nature of much of the financing and the acquisition also adds a layer of scrutiny.

Positives

• Net loss significantly reduced to $1.1 million for the three months ended September 30, 2025, from $6.0 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased to $8.4 million from $13.6 million in the prior year period.
• Cash and cash equivalents increased to $7.3 million as of September 30, 2025, from $1.3 million at December 31, 2024, providing a longer runway.
• Successful equity financing rounds, including $3 million from a related party (Bayshore Trust) and over $6.5 million from an At The Market (ATM) offering, demonstrate continued access to capital.
• Binding Letter of Intent to acquire TELI Pharmaceuticals, Inc. will consolidate worldwide intellectual property rights for Telomir-1, enhancing its commercial value.
• The TELI acquisition includes potential future contributions of up to $5 million from TELI shareholders, tied to key development milestones.
• Extensive positive preclinical data for Telomir-1 across multiple indications (cancer, aging, metabolic, degenerative diseases) supports its multi-target mechanism of action.
• Research and development expenses for the nine months ended September 30, 2025, decreased to $1.1 million from $1.9 million in the prior year period, attributed to a reduction in pharmaceutical manufacturing activities.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $38.9 million as of September 30, 2025.
• A 'going concern' warning indicates substantial doubt about the company's ability to continue operations for at least the next 12 months without additional funding.
• Current cash and cash equivalents are projected to fund operations only through the third quarter of 2026, necessitating further capital raises.
• The company has not generated any revenue since inception and does not anticipate doing so until successful clinical development and regulatory approval, which is uncertain.
• General and administrative expenses increased to $7.3 million for the nine months ended September 30, 2025, primarily due to executive stock-based compensation.
• Cash balances in excess of FDIC limits, approximately $7.1 million as of September 30, 2025, expose the company to potential loss if financial institutions fail.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for a period of twelve months from the issuance date of this report.
• The company's ability to fund ongoing operations and future clinical trials is dependent on obtaining significant additional external funding in the near term, with no assurance of achieving fundraising on commercially reasonable terms, if at all.
• There is no assurance that preclinical results for Telomir-1 will translate into clinical safety or efficacy in humans.
• The company has not generated any revenue and does not expect to until successful preclinical and clinical development, regulatory approval, and commercialization, the timing of which is unknown.
• Expenses are expected to increase substantially as Telomir-1 advances into clinical trials and regulatory approvals are pursued.
• The closing of the TELI Pharmaceuticals acquisition is subject to customary conditions, including due diligence, definitive agreements, and shareholder/board approval, with no assurance the transaction will be completed.
• The company is exposed to market risk, though as a smaller reporting company, detailed quantitative and qualitative disclosures are not required.
• The company relies on third-party suppliers, manufacturers, and service providers, and their adequate performance is crucial for product development.
• The company's ability to obtain and maintain regulatory approval for its product candidates is uncertain and costly.
• The potential market size, opportunity, and growth for product candidates, if approved, are subject to various factors including competition and market acceptance.

Future Outlook

The company expects its expenses to increase substantially as it advances Telomir-1 into and through clinical trials and pursues regulatory approvals, requiring significant investment in clinical trials, regulatory support, and contract manufacturing. It also anticipates evaluating opportunities to acquire or in-license additional product candidates. The company does not expect to generate revenue until successful preclinical and clinical development, regulatory approval, and commercialization, the timing of which is unknown. Management expects to continue generating losses and will require additional debt and/or equity capital to fund future operations beyond the third quarter of 2026.

Management Comments

• Management believes Telomir-1, a novel oral small molecule metal ion regulator, is designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression.
• The proposed acquisition of TELI Pharmaceuticals, Inc. is expected to establish Telomir as the single global owner of Telomir-1 intellectual-property assets and enhance the company's ability to pursue future strategic collaborations, licensing arrangements, or regional partnership opportunities.
• Management acknowledges that the company will continue to generate losses and have insufficient cash and cash equivalents on hand to support its operations for at least the 12 months following the date the financial statements are issued, raising substantial doubt about its ability to continue as a going concern.

Industry Context

Telomir Pharmaceuticals operates in the highly speculative pre-clinical stage biotechnology sector, characterized by significant R&D expenses, long development timelines, and high regulatory hurdles. The focus on epigenetic mechanisms, telomere maintenance, and metal ion regulation positions Telomir-1 in a cutting-edge area of drug discovery targeting complex diseases like cancer, aging, and neurodegeneration. The company's reliance on equity financing and related-party investments is typical for early-stage biotechs that have not yet achieved clinical milestones or generated revenue. The strategic move to consolidate global intellectual property for its lead candidate is a common step for companies aiming to maximize future commercial value and attract larger partners.

Comparison to Industry Standards

• Telomir's pre-clinical stage and lack of revenue are standard for early-stage biotechnology companies, which typically incur substantial losses from research and development.
• The 'going concern' warning is a significant concern, though not uncommon for biotechs that have not yet reached commercialization and rely heavily on external funding.
• The successful capital raises, particularly from related parties and through an ATM facility, demonstrate a capacity to attract funding, which is crucial for pre-clinical companies, though it also highlights the challenge of securing non-related party institutional investment at this stage.
• The extensive preclinical data reported for Telomir-1 across multiple disease models (cancer, Progeria, AMD, Wilsons disease, Type 2 diabetes) suggests a broad potential, which could be a differentiator if these results translate to human trials, similar to other multi-indication drug candidates in early development.
• The strategy to acquire worldwide rights for Telomir-1 through a related-party transaction (TELI Pharmaceuticals) is a common approach for consolidating intellectual property and streamlining future commercialization efforts, aligning with practices seen in other emerging biopharma companies seeking to control their core assets globally.

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are pending against the company that are expected to have a material adverse effect on its business and financial condition.
• The company anticipates expending significant financial and managerial resources in the future to defend its intellectual property rights and to defend against claims of infringement by third parties.

Related Party Transactions

• The company licenses U.S. patent rights for Telomir-1 from MIRALOGX, LLC, an intellectual property development and holding company established by the company's founder, Jonnie R. Williams, Sr. The agreement includes an 8% royalty on net sales and non-royalty bearing milestone revenue, with no payments made to date.
• Working capital advances of $0.1 million from companies under common control remain outstanding as of September 30, 2025, which are due on demand and non-interest bearing.
• On September 24, 2024, the company entered into an unsecured Promissory Note and Loan Agreement (Starwood Note) with the Starwood Trust, a related party trust established by the company's founder, for up to $5 million at 7% per annum interest. No amounts have been borrowed as of September 30, 2025.
• On December 9, 2024, Starwood Trust purchased 142,857 shares of unregistered common stock for $1.0 million.
• On May 19, 2025, the company entered into an agreement to raise $3 million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated with the company's largest shareholder. This involved issuing 1,000,000 restricted shares.
• On October 17, 2025, the company executed a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., a related party company, to secure worldwide rights to Telomir-1. The transaction involves exchanging TELI common stock for Telomir common stock and includes up to $5 million in potential contributions from certain TELI shareholders.

Stakeholder Impact

• Shareholders face potential dilution from ongoing and future equity financings (ATM offering, Bayshore Trust investment) but also stand to benefit from the consolidation of global IP rights for Telomir-1 and promising preclinical developments.
• Employees and management benefit from significant stock-based compensation, aligning their interests with company performance.
• Creditors, particularly related parties, have provided significant financing and advances, indicating their continued support but also exposing them to the company's financial risks.
• The company's ability to continue operations and advance Telomir-1 is critical for all stakeholders, as it directly impacts the potential for future value creation and the realization of its therapeutic goals.

Next Steps

• Advance Telomir-1 into and through clinical trials and pursue regulatory approvals.
• Seek significant additional external funding through debt and/or equity financings to support ongoing operations and future clinical trials.
• Complete due diligence, negotiate definitive agreements, and obtain shareholder and board approvals for the acquisition of TELI Pharmaceuticals, Inc.
• Evaluate opportunities to acquire or in-license additional product candidates and technologies.
• Continue preclinical activities and studies for Telomir-1.

Key Dates

Recommendation

The company presents a high-risk, high-reward profile typical of pre-clinical biotechnology firms. While the 'going concern' warning and continued losses are significant negatives, the company has demonstrated an ability to raise capital, including substantial related-party investments, which provides a near-term cash runway. The extensive and promising preclinical data for Telomir-1 across multiple indications, coupled with the strategic move to consolidate global intellectual property, offers considerable long-term upside potential. However, the path to commercialization is long, costly, and uncertain. A 'hold' recommendation reflects the balance between these inherent risks and the potential for future value creation, suggesting that current investors maintain their position while closely monitoring clinical development milestones and future financing activities.

Keywords

Biotechnology, Telomir-1, Preclinical, Cancer, Aging, Degenerative Disease, Epigenetics, DNA Methylation, Telomere, Metal Ion Regulator, Oncology, Metabolic, AMD, Progeria, Wilsons Disease, Alzheimers, Type 2 Diabetes, Triple-Negative Breast Cancer, Prostate Cancer, Pancreatic Cancer, Equity Financing, ATM Offering, SEC Filing, 10-Q, Going Concern